Folic Acid–Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting
暂无分享,去创建一个
Maria Paola Costi | F. Spyrakis | G. Ponterini | G. Cannazza | R. Guerrini | L. Losi | S. Ferrari | S. Pacifico | G. Marverti | C. Marraccini | A. Martello | D. D’Arca | Gaia Gozzi | Angela Lauriola | M. Santucci | A. S. Cazzato | Lorenzo Tagliazucchi
[1] G. Peters,et al. RX-3117 (Fluorocyclopentenyl-Cytosine)-Mediated Down-Regulation of DNA Methyltransferase 1 Leads to Protein Expression of Tumor-Suppressor Genes and Increased Functionality of the Proton-Coupled Folate Carrier , 2020, International journal of molecular sciences.
[2] Cesar M. Castro,et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. , 2020, Gynecologic oncology.
[3] Maria Paola Costi,et al. pH-Promoted Release of a Novel Anti-Tumour Peptide by “Stealth” Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells , 2018, Pharmaceutical Research.
[4] Maria Paola Costi,et al. Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth. , 2018, Journal of medicinal chemistry.
[5] J. Reddy,et al. Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic , 2018, Scientific Reports.
[6] V. Chudasama,et al. Advances in targeting the folate receptor in the treatment/imaging of cancers , 2017, Chemical science.
[7] J. Reddy,et al. Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy , 2017, Cancer Chemotherapy and Pharmacology.
[8] L. Matherly,et al. Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates , 2017, Molecular Cancer Therapeutics.
[9] Maria Paola Costi,et al. Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology , 2016, Scientific Reports.
[10] Kristina M. Ilieva,et al. Targeting folate receptor alpha for cancer treatment , 2016, Oncotarget.
[11] P. Low,et al. Synthesis and Evaluation of Folate-Conjugated Phenanthraquinones for Tumor-Targeted Oxidative Chemotherapy , 2016, Open journal of medicinal chemistry.
[12] Maria Paola Costi,et al. Enhanced anti-hyperproliferative activity of human thymidylate synthase inhibitor peptide by solid lipid nanoparticle delivery. , 2015, Colloids and surfaces. B, Biointerfaces.
[13] Maria Paola Costi,et al. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[14] Maria Paola Costi,et al. Alanine mutants of the interface residues of human thymidylate synthase decode key features of the binding mode of allosteric anticancer peptides. , 2015, Journal of medicinal chemistry.
[15] Maria Paola Costi,et al. Internalization and stability of a thymidylate synthase Peptide inhibitor in ovarian cancer cells. , 2014, Journal of medicinal chemistry.
[16] Maria Paola Costi,et al. Mass spectrometric/bioinformatic identification of a protein subset that characterizes the cellular activity of anticancer peptides. , 2014, Journal of proteome research.
[17] James D. Brenton,et al. Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes , 2014, PloS one.
[18] P. Johnston,et al. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy , 2014, Nature Reviews Clinical Oncology.
[19] Maria Paola Costi,et al. Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth. , 2014, Journal of medicinal chemistry.
[20] Maria Paola Costi,et al. Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells. , 2013, International journal of oncology.
[21] R. Bischoff,et al. High-sensitivity LC-MS/MS quantification of peptides and proteins in complex biological samples: the impact of enzymatic digestion and internal standard selection on method performance. , 2013, Analytical chemistry.
[22] C. Dann,et al. Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition , 2013, Proceedings of the National Academy of Sciences.
[23] Chen Chen,et al. Structural basis for molecular recognition of folic acid by folate receptors , 2013, Nature.
[24] Maria Paola Costi,et al. Translational repression of thymidylate synthase by targeting its mRNA , 2013, Nucleic acids research.
[25] Maria Paola Costi,et al. Inhibitor of ovarian cancer cells growth by virtual screening: a new thiazole derivative targeting human thymidylate synthase. , 2012, Journal of medicinal chemistry.
[26] H. Myllykallio,et al. Transcriptional Activation and Cell Cycle Block Are the Keys for 5-Fluorouracil Induced Up-Regulation of Human Thymidylate Synthase Expression , 2012, PloS one.
[27] Manfred Rauh,et al. LC-MS/MS for protein and peptide quantification in clinical chemistry. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[28] Rebecca C Wade,et al. The active–inactive transition of human thymidylate synthase: Targeted molecular dynamics simulations , 2011, Proteins.
[29] Yun-Wei Lin,et al. Up-Regulation of Extracellular Signal-Regulated Kinase 1/2-Dependent Thymidylate Synthase and Thymidine Phosphorylase Contributes to Cisplatin Resistance in Human Non–Small-Cell Lung Cancer Cells , 2011, Journal of Pharmacology and Experimental Therapeutics.
[30] A. Oshima,et al. A Gene Expression Signature of Acquired Chemoresistance to Cisplatin and Fluorouracil Combination Chemotherapy in Gastric Cancer Patients , 2011, PloS one.
[31] Maria Paola Costi,et al. Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs. , 2010, Journal of medicinal chemistry.
[32] Maria Paola Costi,et al. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells. , 2009, European journal of pharmacology.
[33] Philip S Low,et al. A Role for the Proton-coupled Folate Transporter (PCFT-SLC46A1) in Folate Receptor-mediated Endocytosis* , 2009, Journal of Biological Chemistry.
[34] Y. Assaraf,et al. The Reduced Folate Carrier (RFC) Is Cytotoxic to Cells under Conditions of Severe Folate Deprivation , 2008, Journal of Biological Chemistry.
[35] Barry A. Siegel,et al. Exploratory Study of 99mTc-EC20 Imaging for Identifying Patients with Folate Receptor–Positive Solid Tumors , 2008, Journal of Nuclear Medicine.
[36] A. Mitra,et al. Folic acid transport via high affinity carrier-mediated system in human retinoblastoma cells. , 2008, International journal of pharmaceutics.
[37] G. Peters,et al. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo , 2008, Cancer Chemotherapy and Pharmacology.
[38] J. Reddy,et al. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. , 2007, Cancer research.
[39] E. Oliveros,et al. Substituent Effects on the Photophysical Properties of Pterin Derivatives in Acidic and Alkaline Aqueous Solutions , 2005, Photochemistry and photobiology.
[40] P. Low,et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. , 2005, Analytical biochemistry.
[41] A. Jackman,et al. Antifolates targeted specifically to the folate receptor. , 2004, Advanced drug delivery reviews.
[42] S. Canevari,et al. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies , 2003, Gene Therapy.
[43] Y. Cho‐Chung,et al. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] Hiroyuki Suzuki,et al. Sequence-specific DNA damage induced by ultraviolet A-irradiated folic acid via its photolysis product. , 2003, Archives of biochemistry and biophysics.
[45] David Cunningham,et al. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] P. Johnston,et al. Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] L. Lebioda,et al. Structure of Human Thymidylate Synthase Suggests Advantages of Chemotherapy with Noncompetitive Inhibitors* , 2001, The Journal of Biological Chemistry.
[48] L. Lebioda,et al. Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug. , 2001, Biochemistry.
[49] P. Low,et al. Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. , 1999, Blood.
[50] P. Low,et al. Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[51] J. Holm,et al. Folate Receptors in Malignant and Benign Tissues of Human Female Genital Tract , 1997, Bioscience reports.
[52] G Toffoli,et al. Overexpression of folate binding protein in ovarian cancers , 1997, International journal of cancer.
[53] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[54] G. Aherne,et al. Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines. , 1995, European journal of cancer.
[55] J. Ross,et al. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications , 1994, Cancer.
[56] R. Ferone,et al. Mode of binding of folate analogs to thymidylate synthase. Evidence for two asymmetric but interactive substrate binding sites. , 1994, The Journal of biological chemistry.
[57] L R Coney,et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. , 1992, Cancer research.
[58] P. Andrews,et al. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. , 1992, Cancer research.
[59] M. Kashani-Sabet,et al. Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[60] Y. Lu,et al. Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin. , 1988, Biochemical pharmacology.
[61] Maria Paola Costi,et al. Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth. , 2018, Vitamins and hormones.
[62] L. Matherly,et al. Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. , 2014, Current topics in membranes.
[63] Chandana Mohanty,et al. Receptor mediated tumor targeting: an emerging approach for cancer therapy. , 2011, Current drug delivery.
[64] P. Low,et al. Folate-mediated targeting: from diagnostics to drug and gene delivery. , 2001, Drug discovery today.